Shares of Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) have been given an average recommendation of "Moderate Buy" by the sixteen ratings firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $311.67.
CRL has been the topic of several recent research reports. Argus set a $330.00 price target on Charles River Laboratories International in a research note on Thursday, September 17th. Evercore set a $330.00 price objective on Charles River Laboratories International in a research note on Friday, September 25th. Barclays boosted their target price on Charles River Laboratories International from $330.00 to $375.00 and gave the stock an "overweight" rating in a report on Thursday, November 5th. JPMorgan Chase & Co. raised Charles River Laboratories International from a "neutral" rating to an "overweight" rating and increased their target price for the stock from $180.00 to $310.00 in a research note on Thursday, August 6th. Finally, Robert W. Baird raised their price target on Charles River Laboratories International from $291.00 to $334.00 and gave the company an "outperform" rating in a report on Friday, September 25th.
Check Out Our Latest Analysis on CRL
Insider Transactions at Charles River Laboratories International
In related news, Director James C. Foster sold 33,561 shares of the company's stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $300.00, for a total value of $10,068,300.00. Following the transaction, the director owned 31,596 shares in the company, valued at $9,478,800. The trade was a 51.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon Parisotto sold 2,156 shares of the stock in a transaction dated Wednesday, October 21st. The shares were sold at an average price of $344.41, for a total transaction of $742,547.96. Following the sale, the executive vice president directly owned 4,807 shares in the company, valued at $1,655,578.87. This trade represents a 30.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 60,740 shares of company stock worth $19,528,128. 1.30% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Charles River Laboratories International
A number of institutional investors have recently made changes to their positions in the company. Physician Wealth Advisors Inc. raised its holdings in Charles River Laboratories International by 127.9% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company's stock worth $29,000 after acquiring an additional 55 shares during the last quarter. Continuum Advisory LLC purchased a new stake in Charles River Laboratories International during the 2nd quarter valued at $30,000. IFP Advisors Inc boosted its stake in Charles River Laboratories International by 182.8% during the 3rd quarter. IFP Advisors Inc now owns 164 shares of the medical research company's stock valued at $48,000 after purchasing an additional 106 shares during the last quarter. Dogwood Wealth Management LLC purchased a new stake in Charles River Laboratories International during the 3rd quarter valued at $56,000. Finally, Cavanaugh Group Inc. bought a new stake in shares of Charles River Laboratories International in the 3rd quarter worth $65,000. Hedge funds and other institutional investors own 98.91% of the company's stock.
Charles River Laboratories International Price Performance
Shares of CRL stock opened at $333.47 on Thursday. The business's fifty day moving average is $314.26 and its 200 day moving average is $230.05. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.76. The stock has a market cap of $15.98 billion, a price-to-earnings ratio of 366.45, a PEG ratio of 3.00 and a beta of 1.36. Charles River Laboratories International has a twelve month low of $146.20 and a twelve month high of $379.63.
Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The medical research company reported $3.09 earnings per share for the quarter, topping analysts' consensus estimates of $2.97 by $0.12. Charles River Laboratories International had a net margin of 1.01% and a return on equity of 16.95%. The business had revenue of $982.73 million for the quarter, compared to analysts' expectations of $960.36 million. During the same quarter in the prior year, the company earned $2.43 earnings per share. The business's revenue was down 2.2% compared to the same quarter last year. Research analysts expect that Charles River Laboratories International will post 11.45 EPS for the current fiscal year.
About Charles River Laboratories International
(
Get Free Report)
Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company's offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Charles River Laboratories International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.
While Charles River Laboratories International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.